Execution of Licensing and Supply Agreement on Uritos® Tablets with SPIMACO
February 27, 2009
KYORIN Co., Ltd. announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd. (Head office: Tokyo, President: Itaru Kojo) has entered into a License and Supply Agreement with Saudi Pharmaceutical Industries & Medical Appliances Corporation ("SPIMACO") (Head office: Riyadh, Saudi Arabia, President: Dr. Abdullah Bin Abdulaziz Al Abdulkader), under which KYORIN Pharmaceutical granted to SPIMACO an exclusive right to develop, register, import, and market Uritos® Tablets (generic name: Imidafenacin), a therapeutic agent for overactive bladder (OAB) in thirteen countries in the Middle East and North Africa (MENA) region, including Saudi Arabia.
Please see the PDF file below for details.
